title: Complete response to sunitinib in a patient with relapsed irresectable renal cell carcinoma.
abstract: We report a case with a complete pathology-proven remission after sunitinib treatment of a relapsed irresectable clear cell renal carcinoma. A significant objective response was observed with tumor size reduction during treatment. After surgery, on pathologic examination it was concluded that the patient exhibited a complete response; activity and the feasibility and safety of subsequent surgical resection were assessed. Otherwise after discontinuing sunitinib, the patient had a relapse on the same location; sunitinib has been resumed and was again found to be effective.
authors.affiliation: Department of Medical Oncology, Ramón y Cajal University Hospital, Madrid, Spain. mavaz.hrc@salud.madrid.org
authors.forename: Maria Angeles
authors.initials: MA
authors.lastname: Vaz
authors.forename: Vanessa
authors.initials: V
authors.lastname: Pachón
authors.forename: Enrique
authors.initials: E
authors.lastname: Grande
authors.forename: Reyes
authors.initials: R
authors.lastname: Ferreiro
authors.forename: Alfredo
authors.initials: A
authors.lastname: Carrato
mesh_terms: D000970:Antineoplastic Agents / Q000627:therapeutic use*; D002292:Carcinoma, Renal Cell / Q000188:drug therapy* / Q000473:pathology / Q000601:surgery; D003131:Combined Modality Therapy; D006801:Humans; D007211:Indoles / Q000627:therapeutic use*; D007680:Kidney Neoplasms / Q000188:drug therapy* / Q000473:pathology / Q000601:surgery; D008297:Male; D008875:Middle Aged; D009364:Neoplasm Recurrence, Local; D011758:Pyrroles / Q000627:therapeutic use*; D012074:Remission Induction / Q000379:methods; D000077210:Sunitinib; D016896:Treatment Outcome
chemical_list: D000970:Antineoplastic Agents; D007211:Indoles; D011758:Pyrroles; D000077210:Sunitinib